Teprotumumab and Thyroid Eye Disease

Drs. Alison Watson and Seanna Grob review recent data on teprotumumab (Tepezza), the only FDA-approved therapy for thyroid eye disease (TED).

CME Information

Release: December 30, 2021; expires December 30, 2024

Disclosures: Dr. Watson has served as a consultant to Horizon Therapeutics. Drs. Grob and Sridhar report no relevant financial disclosures.

Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards in the management of thyroid eye disease or the outcomes from recent research and how these impact patient care decisions.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.